MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1161/jaha.121.023762

Медицинская библиотека · Journal of the American Heart Association · 2022

Amiodarone Use and All-Cause Mortality in Patients With a Continuous-Flow Left Ventricular Assist Device.

Gopinathannair Rakesh, Pothineni Naga Venkata K, Trivedi Jaimin R, Roukoz Henri, Cowger Jennifer, Ahmed Mustafa M, Bhan Adarsh, K Ravichandran Ashwin, Bhat Geetha, Al Ahmad Amin, Natale Andrea, Di Biase Luigi, Slaughter Mark S, Lakkireddy Dhanunjaya

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

Background Atrial and ventricular arrhythmias are commonly encountered in patients with advanced heart failure, with amiodarone being the most commonly used antiarrhythmic drug in continuous-flow left ventricular assist device (CF-LVAD) recipients. The purpose of this study was to assess the impact of amiodarone use on long-term all-cause mortality in ptients with a CF-LVAD. Methods and Results A retrospective multicenter study of CF-LVAD was conducted at 5 centers including all CF-LVAD implants from 2007 to 2015. Patients were stratified based on pre-CF-LVAD implant amiodarone use. Additional use of amiodarone after CF-LVAD implantation was also evaluated. Primary outcome was all-cause mortality during long-term follow-up. Kaplan-Meier curves were used to assess survival outcomes. Multivariable Cox regression was used to identify predictors of outcomes. Propensity matching was done to address baseline differences. A total of 480 patients with a CF-LVAD (aged 58±13 years, 81% men) were included. Of these, 170 (35.4%) were on chronic amiodarone therapy at the time of CF-LVAD implant, and 310 (64.6%) were not on amiodarone. Rate of all-cause mortality over the follow-up period was 32.9% in the amiodarone group compared with 29.6% in those not on amiodarone (P=0.008). Similar results were noted in the propensity-matched group (log-rank, P=0.04). On multivariable Cox regression analysis, amiodarone use at baseline was independently associated with all-cause mortality (hazard ratio, 1.68 [95% CI, 1.1-2.5]; P=0.01). Conclusions Amiodarone use was associated with significantly increased rates of all-cause mortality in CF-LVAD recipients. Earlier interventions for arrhythmias to avoid long-term amiodarone exposure may improve long-term outcomes in CF-LVAD recipients and needs further study.

Для цитирования: Gopinathannair Rakesh, Pothineni Naga Venkata K, Trivedi Jaimin R, Roukoz Henri, Cowger Jennifer, Ahmed Mustafa M, Bhan Adarsh, K Ravichandran Ashwin, Bhat Geetha, Al Ahmad Amin, Natale Andrea, Di Biase Luigi, Slaughter Mark S, Lakkireddy Dhanunjaya. Amiodarone Use and All-Cause Mortality in Patients With a Continuous-Flow Left Ventricular Assist Device.. Journal of the American Heart Association. 2022. DOI: 10.1161/jaha.121.023762.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.